OGX-427 Plus Chemotherapy for Advanced Bladder Cancer (UW11028)
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Investigator: Evan Ya-Wen Yu, MD; Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms; Status: Recruiting; Study ID: NCT01454089
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Investigator: Evan Ya-Wen Yu, MD; Conditions: Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis; Status: Recruiting; Study ID: NCT01282463
RTOG 0926 A Phase II Protocol For Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging.
Investigator: George Laramore, MD, PhD; Conditions: Bladder Cancer; Status: Recruiting; Study ID: NCT00981656